References

  1. Donaldson, K. and K. JC., Naturally occurring forms of folic acid. II. Enzymatic conversion of methylenetetrahydrofolic acid to prefolic A-methyl-tetrahydrofolate. J Biol Chem, 1962. 237: p. 1298-304.
  2. Sweeney, M.R., J. McPartlin, and J. Scott, Folic acid fortification and public health: report on threshold doses above which unmetabolised folic acid appear in serum. BMC Public Health, 2007. 7: p. 41.
  3. Wagner, C., Cellular folate binding proteins; function and significance. Annu Rev Nutr, 1982. 2: p. 229-48.
  4. Spector, R. and A.V. Lorenzo, Folate transport in the central nervous system. Am J Physiol, 1975. 229(3): p. 777-82.
  5. Selhub, J., Folate, vitamin B12 and vitamin B6 and one carbon metabolism. J Nutr Health Aging, 2002. 6(1): p. 39-42.
  6. Wright, A.J., J.R. Dainty, and P.M. Finglas, Folic acid metabolism in human subjects revisited: potential implications
  7. Chen, Z., A.C. Karaplis, S.L. Ackerman, I.P. Pogribny, S. Melnyk, S. Lussier-Cacan, M.F. Chen, A. Pai, S.W. John, R.S.Smith, T. Bottiglieri, P. Bagley, J. Selhub, M.A. Rudnicki, S.J. James, and R. Rozen, Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet, 2001. 10(5): p. 433-43.
  8. Willems FF, Boers GH, Blom HJ, et al. Pharmacokinetic Study on the Utilization of 5-methyltetrahydrofolate and Folic Acid in Patients with Coronary Artery Disease. Br J Pharmacol 2004;141:825-830.
  9. 5-Methyltetrahydrofolate.(Monograph), Alternative Medicine Review, 2006. 11(4):330-337
  10. Charles Deborah H. M., Ness Andy R., Campbell Doris, Smith George Davey, Whitley Elise, and Hall Marion H.: Folic acid supplements in pregnancy and birth outcome: re-analysis of a large randomized controlled trial and update of Cochrane review. Paediatric and Perinatal Epidemiology 2005; Vol 19:112-124.
  11. Cleary-Goldman Jane, Malone Fergal D., Vidaver John, Ball Robert H., Nyberg David A., Comstock Christine H., Saade George R., Eddleman Keith A., Klugman Susan, Dugoff Lorraine, Timor-Tritsch Ilan E., Craigo Sabrina D., Carr Stephen R., Wolfe Honor M., Bianchi Diana W., and D'Alton Mary for the FASTER Consortium. Obstetrics & Gynecology 2005; Vol. 105, No. 5:983-990.
  12. Relton Caroline L., Pearce Mark S., and Parker Louise: The influence of erythrocyte folate and serum vitamin B12 status on birth weight. British Journal of Nutrition 2005; Vol. 93:593-99.
  13. Tamura Tsunenobu and Picciano Mary Frances: Folate and human reproduction. Am J Clin Nutr 2006; 83:993-1016.
  14. Murphy M, Scott J, Arija V, Molloy A, Fernandez-Ballart J. Maternal homocysteine before conception and throughout pregnancy predicts fetal homocysteine and birth weight.
  15. Murphy MM, Fernandez-Ballart JD, Arija V, Scott J.M, Molloy AM, Canals J. Maternal homocysteine at preconception is negatively associated with cognitive achievement in children at 4 months and 6 years of age. Clinical Chemistry & Laboratory Medicine. 45(5):A23, May 2007
  16. Wilson RD, Johnson JA, Wyatt P, et al. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obste Gynaeco Can. 2007 Dec; 29(12):1003-26.
  17. Sinclair K, Allegrucci C, Singh R, Gardner D, Sebastian, et al. DNA methylation, insulin resistance and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. PNAS 2007 vol. 104 no.9
  18. Lamers Yvonne, Prinz-Langenohl Reinhild, Bramswig Susanne, and Pietrzik Klaus: Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age. Am J Clin Nutr 2006; 84:156-61.
  19. Houghton Lisa A, Sherwood Kelly L, Pawlosky Robert, Ito Shinya, and O'Connor Deborah L: [6S]-5-methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. Am J Clin Nutr 2006;83:842-50
  20. Ryan-Harshman M, Aldoori W. Folic acid and prevention of neural tube defects. Can Fam Physician. 2008 Jan:54(1):36-8.
  21. Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet. 2001 Dec 15;358(9298):2069-73.
  22. Botto Lorenzo D, and Yang Quanhe: 5,10-Methylenetetrahydrofolate Reductase Gene Variants and Congenital Anomalies: A HuGE Review. American Journal of Epidemiology 2000;Vol 151, No.9:862-77.
  23. Kirke Peadar N, Mills James L, Molloy Anne M, Brody Lawrence C, O'Leary Valerie B, Daly Leslie, Murray Sharon, Conley Mary, Mayne Philip D, Smith Owen, and Scott John M: Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. BMJ 2004;Vol 328:1535-6.
  24. Molloy Anne M, Daly Sean, Mills James L, Kirke Peader N, Whitehead Alexander S, Ramsbottom Dorothy, Conley Mary R, Weir Donald G, and Scott John M: Thermolabile variant of 5,10-Methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. The Lancet 1997;Vol 349:1591-93.
  25. B Akoglu, M Schrott, H Bolouri, A Jaffari, E Kutschera, WF Caspary and D Faust: The Folic Acid Metabolite L-5-Methyltetrahydrofolate Effectively Reduces Total Serum Homocysteine Level in Orthotopic Liver Transplant Recipients: A Double-Blind Placebo-Controlled Study. European Journal of Clinical Nutrition (2007), 1-6
  26. Lowenthal EA, Mayo MS, Cornwell PE, Thornley-Brown D. Homocysteine elevation in sickle cell disease. J Am Coll Nutr. 2000 Oct;19(5):608-12.
  27. Caruso R, Campolo J, et al. Effect of homocysteine lowering by 5 methyltetrahydrofolate on redox status in hyperhomocysteinemia. J. Cardiovasc Pharmaco. 2006 Apr; 47(4):549-55.
  28. Hardman J, Limbird L (Editors-in-Chief) Goodman and Gilman's The Pharmacological Basis of Therapeutics Ninth Edition. Chapter 53: Hematopoietic Agents; p 1334-36.
  29. van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 2001 Nov; 44(11):2525-30.
  30. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 2002 Apr; 12(3):183-90.
  31. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation of the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multi-center, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001 Jul; 44(7):1515-24
  32. Scott JM, Weir DG: The Methylfolate Trap. A Physiological Response in Man to Prevent Methyl Group Deficiency in Kwashiokor and an Explanation for Folic-Acid-Induced Exacerbation of Subacute Combined Degeneration in Pernicious Anemia; Lancet. 1981 2:337-340
  33. United States Food and Drug Administration Title 21 Code of Federal Regulations 101.9(j) (8).
  34. PDR® For Nutritional Supplements, 2001;ISBN: 1-56363-364-7:157-167.
  35. Leucovorin Calcium (folinic acid) For Injection Prescribing Information:December 2003; Mayne Pharma (USA) Inc.
  36. Depakote® (divalproex sodium) Prescribing Information:January 2006; Abbott Laboratories.
  37. Topamax® (topiramate) Prescribing Information:June 2005; ORTHO-McNEIL NEUROLOGICS, INC.
  38. Neurontin® (gabapentin) Prescribing Information:December 2005; Parke-Davis.
  39. YAZ® (drospirenone & ethinyl estradiol) Prescribing Information:February 2007; Bayer Healthcare Pharmaceuticals, Inc.
  40. Lyrica® (pregabalin) Prescribing Information:March 2006; Parke-Davis.
  41. Keppra® (levetiracetam) Prescribing Information: March 2007; UCB, Inc.
  42. Gabitril (tiagabine) Prescribing Information: March 2005: Cephalon, Inc.
  43. Zonegran® (zonisamide) Prescribing Information: December 2004: Elan Pharma International Ltd.; licensed to Eisai Inc.

Zervalx™ is an orally administered prescription medical food for the dietary management of the following patient conditions:
preconception hyperhomocysteinemia; and/or, intermediate- to higher- risk pregnancies which require an increased dietary folate intake; and/or, hemolytic, megaloblastic, and/or sickle cell anemia complicated by folate deficiency; and/or experiencing methotrexate induced plasma hyperhomocysteinemia. Zervalx™ should always be used under the supervision of a physician.

© 2008, Pamlab, LLC, Covington, LA. (985) 893-4097 Zervalx is a registered trademark of Pamlab, L.L.C. All rights reserved.

Home Site Map